Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis
Open Access
- 6 November 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in Breast Cancer Research
- Vol. 15 (6), R105
- https://doi.org/10.1186/bcr3572
Abstract
Obesity is an unfavorable prognostic factor in breast cancer (BC) patients regardless of menopausal status and treatment received. However, the association between obesity and survival outcome by pathological subtype requires further clarification.Keywords
This publication has 40 references indexed in Scilit:
- Obesity at diagnosis is associated with inferior outcomes in hormone receptor‐positive operable breast cancerCancer, 2012
- Race and Hormone Receptor–Positive Breast Cancer Outcomes in a Randomized Chemotherapy TrialJNCI Journal of the National Cancer Institute, 2012
- Global burden of obesity in 2005 and projections to 2030International Journal of Obesity, 2008
- Randomized Phase 3 Trial of Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast CancerJNCI Journal of the National Cancer Institute, 2008
- Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studiesThe Lancet, 2008
- Epidemiology of basal-like breast cancerBreast Cancer Research and Treatment, 2007
- Relation between chemotherapy dose, oestrogen receptor expression, and body-mass indexThe Lancet, 2005
- Adjuvant Docetaxel for Node-Positive Breast CancerThe New England Journal of Medicine, 2005
- Overweight, obesity and cancer: epidemiological evidence and proposed mechanismsNature Reviews Cancer, 2004
- Breast cancer and hormone-replacement therapy in the Million Women StudyThe Lancet, 2003